UID:
almafu_9961427229302883
Format:
1 streaming video file (1 hour, 11 min., 03 sec.) :
,
sound, color.
,
011103
Series Statement:
Henry Stewart talks
Content:
Audio-visual presentation : Antagonist monoclonal antibodies to VEGFR-3 ; Mode of action of antagonist monoclonal antibodies ; Functional properties of antagonist antibodies to VEGFR-3 ; In vivo effects of anti-VEGFR-3 treatment on physiological lymphangiogenesis ; Inhibition of pathological vessel growth in the cornea ; Anti-angiogenic effect of antibodies to VEGFR-3 in tumors ; Inhibition of lymphatic metastasis with antagonist antibodies to VEGFR-3 ; Role of VEGFR-3 in normal and pathological immune response.
Note:
Retrieved April 12, 2024, from https://hstalks.com/bs/465/.
,
Introduction -- Angiogenesis-VEGF -- Angiogenesis-VEGF-C/D -- VEGF and VEGFR tyrosine kinase -- Strategies to inhibit VEGFR signaling -- MuMAb VEGF A4.6.1 -- RhuMAb VEGF-Avastin -- Blocking Ab differ from other agents -- Anti-VEGF Ab prevents VEGF/VEGFR interaction -- Potential effects of inhibiting VEGF -- Anti-angiogenesis 'normalises' tumour vasculature -- Anti-VEGF Ab modifies tumor vasculature -- VEGF inhibition can induce capillary regression -- Ranibizumab -- Pegaptanib -- 'Metronomic' anti-angiogenic chemotherapy -- Preclinical models -- Potential effects of anti-VEGF therapy -- Anti-VEGFR2 mAb -- Treatment of human xenograft tumors with DC101 -- VEGFR-2 blockade -- VEGFR-2 block leads to increase in tumor hypoxia -- Anti-VEGFR-2 mAb and gemcitabine -- VEGFR-2 Ab IMC-1121b -- Structure and properties of VEGF trap -- Angiogenesis inhibitors in clinical trials -- Conclusions (1) -- Conclusions (2) -- Inhibitors of lymphangiogenesis -- Tumor lymphangiogenesis and metastasis -- VEGF-C/D trap prevents VEGFR-3 signaling -- VEGF-C/D trap prevents lymph vessels growth -- Inhibition of lymphangiogenesis with VEGFR-3-Fc -- Blocking metastasis to lymph nodes -- Model of lymphatic metastasis -- Model of prevention of lymphatic metastasis -- Proteolytic processing of VEGF-C/D -- VEGF in hematogenous and lymphatic spread -- Antagonist monoclonal Abs to VEGFR-3 -- Soluble receptors (traps) and antagonist antibodies -- Antagonist monoclonal antibodies to VEGFR-3 -- Mode of action of antagonist mAbs to RTKs -- Functional properties of alpha-VEGFR-3 mAbs -- Dermal lymphatic regeneration model in mouse -- Systemic alpha-VEGFR-3 treatment -- Angio- and lymphangiogenesis blocking -- Alpha-VEGFR-3 inhibits growth of carcinomas -- Alpha-VEGFR-3 inhibits metastasis of carcinoma -- VEGF-C induces hypertrophy of lymphatic vessels -- Alpha-VEGFR-3 inhibits lymph vessels hypertrophy -- Alpha-VEGFR-3 reduces metastasis to lymph -- The role of VEGFR-3 in inflammation -- Expansion of the lymphatic network -- Prevention of lymphatic hyperplasia -- Alpha-VEGFR-3 modulates adaptive immunity -- VEGF-C, VEGFR-3 and inflammation (1) -- VEGF-C, VEGFR-3 and inflammation (2) -- Rejection of renal transplants -- Conclusions (3).
Language:
English
Bookmarklink
